Lv4
490 积分 2024-04-27 加入
Gastric Cancer
4小时前
待确认
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
9天前
已完结
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma
10天前
已完结
Targeted Therapies in Non–Small Cell Lung Cancer
11天前
已完结
Cutting edge therapies: A review of Food and Drug Administration‐ approved drugs for non‐small cell lung cancer
11天前
已完结
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
24天前
已完结
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
24天前
已完结
Nivolumab and Cabozantinib Combination Therapy Demonstrates Sustained Efficacy in Metastatic Renal Cell Carcinoma
24天前
已关闭
The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database
26天前
已完结
Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer
26天前
已完结
皖公网安备34019202002308
